Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D

Background & Aims: Portal hypertension (PH) drives decompensation in patients with advanced chronic liver disease. Effects of antiviral treatment with bulevirtide (BLV) and achievement of suggested treatment endpoints on PH in patients with chronic hepatitis D (CHD) are unknown. Methods: BLV-tre...

Description complète

Détails bibliographiques

Auteurs principaux:	Lisa Sandmann, Mathias Jachs, Tammo L. Tergast, Lukas Hartl, Birgit Bremer, Martin A. Kabelitz, Michael Schwarz, Julius F.M. Egge, Lorenz Balcar, Benedikt Silvester Hofer, Christine S. Falk, Albert Friedrich Stättermayer, Markus Cornberg, Michael Trauner, Katja Deterding, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2026-01-01
Collection:	JHEP Reports
Sujets:	HDV CSPH HVPG Viral hepatitis
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589555925003258
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!